[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 2493 Introduced in Senate (IS)]

<DOC>






118th CONGRESS
  1st Session
                                S. 2493

To require the Medicare Payment Advisory Commission (MedPAC) submit to 
  Congress two reports on arrangements with pharmacy benefit managers 
        with respect to prescription drug plans and MA-PD plans.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             July 25, 2023

 Mr. Warner (for himself, Mr. Thune, Ms. Cortez Masto, and Mr. Tillis) 
introduced the following bill; which was read twice and referred to the 
                          Committee on Finance

_______________________________________________________________________

                                 A BILL


 
To require the Medicare Payment Advisory Commission (MedPAC) submit to 
  Congress two reports on arrangements with pharmacy benefit managers 
        with respect to prescription drug plans and MA-PD plans.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``PBM Reporting Transparency Act''.

SEC. 2. MEDPAC REPORTS ON AGREEMENTS WITH PHARMACY BENEFIT MANAGERS 
              WITH RESPECT TO PRESCRIPTION DRUG PLANS AND MA-PD PLANS.

    (a) In General.--The Medicare Payment Advisory Commission shall 
submit to Congress the following reports:
            (1) Not later than March 31, 2026, a report on agreements 
        with pharmacy benefit managers with respect to prescription 
        drug plans and MA-PD plans. Such report shall include--
                    (A) a description of trends, including high-level 
                averages and totals for each of the types of 
                information submitted;
                    (B) an analysis of any differences in agreements 
                and their effects on plan enrollee out-of-pocket 
                spending and average pharmacy reimbursement, and any 
                other impacts; and
                    (C) any recommendations the Commission determines 
                appropriate.
            (2) Not later than March 31, 2028, a report describing any 
        changes with respect to the information described in paragraph 
        (1) over time, together with any recommendations the Commission 
        determines appropriate.
    (b) Confidentiality.--The Commission shall not report in a manner 
that would identify a specific pharmacy benefit manager or their 
affiliates, PDP sponsor, MA organization, or plan, or the prices 
charged for specific drugs.
                                 <all>